Trichome Pharma Prepares a Greenhouse in Andalusia to Grow Medical Cannabis

The medical cannabis market is getting closer in Spain. The Spanish company Trichome Pharma specialized in medical cannabis is working together with the Institute of Natural Resources and Agrobiology of Seville (Irnas), a center attached to the Higher Council for Scientific Research (Csic), to create a greenhouse to grow medical cannabis.

The project foresees the exploitation of a plot of one hundred square meters, in which up to 20,000 seedlings would be produced per month. These, initially, will form part of the research and development (R&D) process, to later be commercialized, once the necessary permits are processed and accepted.

Within the framework of this agreement, to delve into medical cannabis, the Irnas-Csic Plant Crop Biotechnology Unit (Ubcv) is included, which pursues the use of the cannabis plant in a sustainable and homogeneous way, in order to allow achieve optimal performance and delve into the genetic improvement of Cannabis sativa L.

If you want to read more about Trichome Pharma and to find the latest business news of the day, download for free our companion app, Born2Invest

Trichome Pharma envisions a greenhouse that will produce 20,000 seedlings per month

These agreements are added to the one that Trichome Pharma made at the end of 2022 with the Andalusian Institute for Agricultural, Fisheries, Food and Organic Production Research and Training (Ifapa) to work together in the selection and study process of various genetics, for this the cultivation will be carried out following the practices of organic farming both in greenhouses and outdoors.

The pharmaceutical company sees it necessary to make agreements with public and private companies, since “we are building an open innovation ecosystem in which public organizations and private companies can collaborate to contribute to the advancement of the cannabis industry in Spain”, says the founder of Trichome Pharma, Nicholas Balk.

Among its agreements for the development of R&D projects, it is worth highlighting the agreement made with Analytica Alimentaria, a company in charge of food safety and quality controls, which will carry out analysis of cannabis samples using methods such as gas chromatography and liquids.

The construction of the Trichome Pharma greenhouse will occupy 100 square meters

To all these agreements must be added the support of the European Union for this project since, thanks to an investment from the European Regional Development Fund  (Feder 2021-2027) through a line of co-financing from the Center for Industrial Technological Development (Cdti) to develop the research project that focuses on crop yield strategies for varieties of Cannabis sativa L., as well as optimization and quality control of pharmacologically active ingredients. 

The use of medical cannabis in Spain is still not regulated. In mid-2022, the Health Commission approved the opinion to implement the necessary measures to legalize medical cannabis, despite the fact that the agreement was supported by all political groups except for the abstention of ERC and EH Bildu, as well as the vote against PP and VOX, the deadline for the project expired in December 2022 and remained unresolved. It is thus a stagnant law that would not yet affect the Trichome Pharma company since they are in an early stage of development and research.

__

(Featured image by Richard T via Unsplash)

DISCLAIMER: This article was written by a third-party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.